[go: up one dir, main page]

CN117327027A - Ligand compound with oxazole structure, preparation method thereof and nickel catalyst - Google Patents

Ligand compound with oxazole structure, preparation method thereof and nickel catalyst Download PDF

Info

Publication number
CN117327027A
CN117327027A CN202311259727.7A CN202311259727A CN117327027A CN 117327027 A CN117327027 A CN 117327027A CN 202311259727 A CN202311259727 A CN 202311259727A CN 117327027 A CN117327027 A CN 117327027A
Authority
CN
China
Prior art keywords
compound
substituent
nickel catalyst
present disclosure
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202311259727.7A
Other languages
Chinese (zh)
Inventor
陈昶乐
聂楠
彭丹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Science and Technology of China USTC
Original Assignee
University of Science and Technology of China USTC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Science and Technology of China USTC filed Critical University of Science and Technology of China USTC
Priority to CN202311259727.7A priority Critical patent/CN117327027A/en
Publication of CN117327027A publication Critical patent/CN117327027A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F110/00Homopolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond
    • C08F110/02Ethene

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本公开提出了一种具有噁唑结构的配体化合物,其结构如式(Ⅰ)所示,其中,R1选自甲基、二苯甲基中的任意一种;Ar选自萘基、苯并噻吩基、取代或未取代的苯中的一种,当上述取代或未取代的苯具有取代基时,取代基选自吸电子取代基或供电子取代基。

The present disclosure proposes a ligand compound with an oxazole structure, whose structure is shown in formula (I), Among them, R1 is selected from any one of methyl and benzyl; Ar is selected from one of naphthyl, benzothienyl, substituted or unsubstituted benzene, when the above-mentioned substituted or unsubstituted benzene has When a substituent is used, the substituent is selected from an electron-withdrawing substituent or an electron-donating substituent.

Description

具有噁唑结构的配体化合物及制备方法、镍催化剂Ligand compound with oxazole structure and preparation method, nickel catalyst

技术领域Technical Field

本公开属于有机合成技术领域,具体涉及具有噁唑结构的化合物及制备方法、镍催化剂。The present invention belongs to the technical field of organic synthesis, and in particular relates to a compound having an oxazole structure, a preparation method, and a nickel catalyst.

背景技术Background Art

近年来,后过渡金属催化剂的发现促进了烯烃聚合领域的快速发展,通过催化剂的结构设计来调控烯烃聚合过程一直是该领域的前沿科学问题。由于金属镍的成本低、丰度高,镍催化剂在烯烃聚合领域展现出广阔的应用前景。1978年,SHOP催化剂的发现引起了世界各地研究人员的广泛关注,其在生产具有Flory分布的α-烯烃方面具有较高的活性。通过SHOP镍催化剂获得的乙烯寡聚物可以作为润滑剂的基本成分和表面改性剂中的功能添加剂,具有很高应用价值。从那时起,通过镍催化剂催化的乙烯配位反应合成乙烯寡聚物被广泛研究。在相关技术中仍还存在探索有效催化合成乙烯寡聚物方案的需要。In recent years, the discovery of late transition metal catalysts has promoted the rapid development of the field of olefin polymerization. The regulation of olefin polymerization process by catalyst structural design has always been a frontier scientific issue in this field. Due to the low cost and high abundance of metallic nickel, nickel catalysts show broad application prospects in the field of olefin polymerization. In 1978, the discovery of SHOP catalyst attracted widespread attention from researchers around the world. It has high activity in producing α-olefins with Flory distribution. Ethylene oligomers obtained by SHOP nickel catalyst can be used as basic components of lubricants and functional additives in surface modifiers, and have high application value. Since then, the synthesis of ethylene oligomers by ethylene coordination reaction catalyzed by nickel catalysts has been widely studied. There is still a need to explore effective catalytic synthesis of ethylene oligomers in related technologies.

发明内容Summary of the invention

有鉴于此,为解决相关技术中的所述以及其他方面的至少一种技术问题,本公开提出了一种具有噁唑结构的配体化合物,其结构如式(Ⅰ)所示,In view of this, in order to solve at least one of the above and other technical problems in the related art, the present disclosure provides a ligand compound having an oxazole structure, the structure of which is shown in formula (I),

其中,R1选自甲基、二苯甲基中的任意一种;Wherein, R 1 is selected from any one of methyl and diphenylmethyl;

Ar选自萘基、苯并噻吩基、取代或未取代的苯中的一种,Ar is selected from naphthyl, benzothiophenyl, substituted or unsubstituted benzene,

当上述取代或未取代的苯具有取代基时,取代基选自吸电子取代基或供电子取代基。When the above-mentioned substituted or unsubstituted benzene has a substituent, the substituent is selected from an electron-withdrawing substituent or an electron-donating substituent.

根据本公开的实施例,具有噁唑结构的配体化合物的吸电子取代基选自三氟甲基、羟基、硝基中的任意一种,供电子取代基选自甲氧基。According to an embodiment of the present disclosure, the electron-withdrawing substituent of the ligand compound having an oxazole structure is selected from any one of trifluoromethyl, hydroxyl, and nitro, and the electron-donating substituent is selected from methoxy.

根据本公开的实施例,具有噁唑结构的配体化合物结构式如下式(Ⅰ-a)~(Ⅰ-c)中的任一所示:According to the embodiments of the present disclosure, the structural formula of the ligand compound having an oxazole structure is shown in any one of the following formulas (I-a) to (I-c):

其中,R2选自三氟甲基、羟基、硝基、甲氧基中的任意一种。Wherein, R2 is selected from any one of trifluoromethyl, hydroxyl, nitro, and methoxy.

在一些具体的实施例中,具有噁唑结构的配体化合物结构式如下所示:In some specific embodiments, the structural formula of the ligand compound having an oxazole structure is as follows:

在本公开的另一方面提出了一种制备上述的配体化合物的方法,包括:In another aspect of the present disclosure, a method for preparing the above-mentioned ligand compound is provided, comprising:

将如式(A)所示的化合物与酮酸甲酯类化合物反应,得到如式(B)所示的化合物;The compound represented by formula (A) is reacted with a keto acid methyl ester compound to obtain a compound represented by formula (B);

将如式(B)所示的化合物与2-氨基-2-甲基-1-丙醇反应,得到如式(C)所示的化合物;The compound represented by formula (B) is reacted with 2-amino-2-methyl-1-propanol to obtain a compound represented by formula (C);

使如式(C)所示的化合物进行自身异构化及脱水反应,得到如式(Ⅰ)所示的化合物。The compound represented by formula (C) is subjected to autoisomerization and dehydration reaction to obtain the compound represented by formula (I).

根据本公开的实施例,化合物(A)与酮酸甲酯类化合物以1:1的摩尔比混合,加入对甲苯磺酸一水合物在140℃~145℃下,分水回流反应40h,重结晶后得到化合物(B);According to an embodiment of the present disclosure, compound (A) and keto acid methyl ester compound are mixed in a molar ratio of 1:1, p-toluenesulfonic acid monohydrate is added, and the mixture is refluxed at 140° C. to 145° C. for 40 h, and compound (B) is obtained after recrystallization;

化合物(B)与2-氨基-2-甲基-1-丙醇以1:2~1:2.5的摩尔比混合,在140℃~145℃下反应24h,分离得到化合物(C);Compound (B) and 2-amino-2-methyl-1-propanol are mixed in a molar ratio of 1:2 to 1:2.5, reacted at 140° C. to 145° C. for 24 hours, and compound (C) is separated;

化合物(C)溶解后,加入三乙胺、4-二甲氨基吡啶、4-甲苯磺酰氯,在80℃~85℃下反应40h,得到配体化合物。After the compound (C) is dissolved, triethylamine, 4-dimethylaminopyridine and 4-toluenesulfonyl chloride are added and reacted at 80° C. to 85° C. for 40 hours to obtain a ligand compound.

在本公开的另一方面提出了一种具有噁唑结构的镍催化剂,其结构如式(II)所示,In another aspect of the present disclosure, a nickel catalyst having an oxazole structure is provided, and its structure is shown in formula (II),

其中,R1选自甲基、二苯甲基中的任意一种;Wherein, R 1 is selected from any one of methyl and diphenylmethyl;

Ar选自萘基、苯并噻吩基、取代或未取代的苯中的一种,Ar is selected from naphthyl, benzothiophenyl, substituted or unsubstituted benzene,

上述取代或未取代的苯具有取代基时,该取代基选自吸电子取代基或供电子取代基;When the substituted or unsubstituted benzene has a substituent, the substituent is selected from an electron-withdrawing substituent or an electron-donating substituent;

其中,吸电子取代基优选为三氟甲基、羟基、硝基中的任意一种;Among them, the electron-withdrawing substituent is preferably any one of trifluoromethyl, hydroxyl, and nitro;

供电子取代基优选为甲氧基。The electron donating substituent is preferably a methoxy group.

根据本公开的实施例,具有噁唑结构的镍催化剂结构式如下式(II-a)~(II-c)中的任一所示:According to an embodiment of the present disclosure, the structural formula of the nickel catalyst having an oxazole structure is shown in any one of the following formulas (II-a) to (II-c):

其中,R2包括三氟甲基、羟基、硝基、甲氧基中的任意一种。Wherein, R 2 includes any one of trifluoromethyl, hydroxyl, nitro, and methoxy.

在一些具体的实施例中,具有噁唑结构的镍催化剂结构式如下所示:In some specific embodiments, the nickel catalyst having an oxazole structure has the following structural formula:

在本公开的另一方面提出了一种制备上述的具有噁唑结构的镍催化剂的方法,包括:In another aspect of the present disclosure, a method for preparing the above-mentioned nickel catalyst having an oxazole structure is proposed, comprising:

将上述具有噁唑结构的配体化合物溶解,与乙二醇二甲醚溴化镍反应,加入正己烷,搅拌过滤,得到镍催化剂。The above ligand compound having an oxazole structure is dissolved, reacted with ethylene glycol dimethyl ether nickel bromide, n-hexane is added, stirred and filtered to obtain a nickel catalyst.

根据本公开的实施例,本公开中通过具有噁唑结构的配体化合物从而合成一种新型具有噁唑结构的镍催化剂。相比于位阻较大的苯胺,噁唑环的空间位阻较小,有利于乙烯的插入,从而提高乙烯聚合活性。同时空间位阻较小的噁唑环与空间位阻较大的苯胺形成不对称结构,有利于乙烯聚合中的链行走过程,从而产生高度支化的聚乙烯。According to the embodiments of the present disclosure, a novel nickel catalyst having an oxazole structure is synthesized by using a ligand compound having an oxazole structure. Compared with aniline having a larger steric hindrance, the oxazole ring has a smaller steric hindrance, which is beneficial to the insertion of ethylene, thereby improving the ethylene polymerization activity. At the same time, the oxazole ring having a smaller steric hindrance forms an asymmetric structure with the aniline having a larger steric hindrance, which is beneficial to the chain walking process in ethylene polymerization, thereby producing highly branched polyethylene.

附图说明BRIEF DESCRIPTION OF THE DRAWINGS

图1为本公开中具有噁唑结构的配体化合物的合成方法流程图;FIG1 is a flow chart of a method for synthesizing a ligand compound having an oxazole structure in the present disclosure;

图2为本公开实施例8中具有噁唑结构的镍催化剂(II-2)的单晶结构示意图;FIG2 is a schematic diagram of the single crystal structure of the nickel catalyst (II-2) having an oxazole structure in Example 8 of the present disclosure;

图3A为本公开实施例1中中间产物(B-1)的核磁共振氢谱图;FIG3A is a hydrogen nuclear magnetic resonance spectrum of the intermediate product (B-1) in Example 1 of the present disclosure;

图3B为本公开实施例1中中间产物(B-1)的核磁共振碳谱图;FIG3B is a carbon NMR spectrum of the intermediate product (B-1) in Example 1 of the present disclosure;

图4A为本公开实施例1中化合物(Ⅰ-1)的核磁共振氢谱图;FIG4A is a hydrogen nuclear magnetic resonance spectrum of compound (I-1) in Example 1 of the present disclosure;

图4B为本公开实施例1中化合物(Ⅰ-1)的核磁共振碳谱图;FIG4B is a carbon NMR spectrum of compound (I-1) in Example 1 of the present disclosure;

图5A为本公开实施例2中中间产物(B-2)的核磁共振氢谱图;FIG5A is a hydrogen nuclear magnetic resonance spectrum of the intermediate product (B-2) in Example 2 of the present disclosure;

图5B为本公开实施例2中中间产物(B-2)的核磁共振碳谱图;FIG5B is a carbon NMR spectrum of the intermediate product (B-2) in Example 2 of the present disclosure;

图6A为本公开实施例2中中间产物(C-2)的核磁共振氢谱图;FIG6A is a hydrogen nuclear magnetic resonance spectrum of the intermediate product (C-2) in Example 2 of the present disclosure;

图6B为本公开实施例2中中间产物(C-2)的核磁共振碳谱图;FIG6B is a carbon NMR spectrum of the intermediate product (C-2) in Example 2 of the present disclosure;

图7A为本公开实施例2中化合物(Ⅰ-2)的核磁共振氢谱图;FIG7A is a hydrogen nuclear magnetic resonance spectrum of compound (I-2) in Example 2 of the present disclosure;

图7B为本公开实施例2中化合物(Ⅰ-2)的核磁共振碳谱图;FIG7B is a carbon NMR spectrum of compound (I-2) in Example 2 of the present disclosure;

图8A为本公开实施例3中中间产物(B-3)的核磁共振氢谱图;FIG8A is a hydrogen nuclear magnetic resonance spectrum of the intermediate product (B-3) in Example 3 of the present disclosure;

图8B为本公开实施例3中中间产物(B-3)的核磁共振碳谱图;FIG8B is a carbon NMR spectrum of the intermediate product (B-3) in Example 3 of the present disclosure;

图9A为本公开实施例3中中间产物(C-3)的核磁共振氢谱图;FIG9A is a hydrogen nuclear magnetic resonance spectrum of the intermediate product (C-3) in Example 3 of the present disclosure;

图9B为本公开实施例3中中间产物(C-3)的核磁共振碳谱图;FIG9B is a carbon NMR spectrum of the intermediate product (C-3) in Example 3 of the present disclosure;

图10A为本公开实施例3中化合物(Ⅰ-3)的核磁共振氢谱图;FIG10A is a hydrogen nuclear magnetic resonance spectrum of compound (I-3) in Example 3 of the present disclosure;

图10B为本公开实施例3中化合物(Ⅰ-3)的核磁共振碳谱图;FIG10B is a carbon NMR spectrum of compound (I-3) in Example 3 of the present disclosure;

图11A为本公开实施例4中中间产物(B-4)的核磁共振氢谱图;FIG11A is a hydrogen nuclear magnetic resonance spectrum of the intermediate product (B-4) in Example 4 of the present disclosure;

图11B为本公开实施例4中中间产物(B-4)的核磁共振碳谱图;FIG11B is a carbon NMR spectrum of the intermediate product (B-4) in Example 4 of the present disclosure;

图12A为本公开实施例4中中间产物(C-4)的核磁共振氢谱图;FIG12A is a hydrogen nuclear magnetic resonance spectrum of the intermediate product (C-4) in Example 4 of the present disclosure;

图12B为本公开实施例4中中间产物(C-4)的核磁共振碳谱图;FIG12B is a carbon NMR spectrum of the intermediate product (C-4) in Example 4 of the present disclosure;

图13A为本公开实施例4中化合物(Ⅰ-4)的核磁共振氢谱图;FIG13A is a hydrogen nuclear magnetic resonance spectrum of compound (I-4) in Example 4 of the present disclosure;

图13B为本公开实施例4中化合物(Ⅰ-4)的核磁共振碳谱图;FIG13B is a carbon NMR spectrum of compound (I-4) in Example 4 of the present disclosure;

图14A为本公开实施例5中中间产物(B-5)的核磁共振氢谱图;FIG14A is a hydrogen nuclear magnetic resonance spectrum of the intermediate product (B-5) in Example 5 of the present disclosure;

图14B为本公开实施例5中中间产物(B-5)的核磁共振碳谱图;FIG14B is a carbon NMR spectrum of the intermediate product (B-5) in Example 5 of the present disclosure;

图15A为本公开实施例5中中间产物(C-5)的核磁共振氢谱图;FIG15A is a hydrogen nuclear magnetic resonance spectrum of the intermediate product (C-5) in Example 5 of the present disclosure;

图15B为本公开实施例5中中间产物(C-5)的核磁共振碳谱图;FIG15B is a carbon NMR spectrum of the intermediate product (C-5) in Example 5 of the present disclosure;

图16A为本公开实施例5中化合物(Ⅰ-5)的核磁共振氢谱图;FIG16A is a hydrogen nuclear magnetic resonance spectrum of compound (I-5) in Example 5 of the present disclosure;

图16B为本公开实施例5中化合物(Ⅰ-5)的核磁共振碳谱图;FIG16B is a carbon NMR spectrum of compound (I-5) in Example 5 of the present disclosure;

图17A为本公开实施例6中化合物(Ⅰ-6)的核磁共振氢谱图;FIG17A is a hydrogen nuclear magnetic resonance spectrum of compound (I-6) in Example 6 of the present disclosure;

图17B为本公开实施例6中化合物(Ⅰ-6)的核磁共振碳谱图;FIG17B is a carbon NMR spectrum of compound (I-6) in Example 6 of the present disclosure;

图18为本公开一实施例中镍催化剂(II-1)的优化结构立体图;以及FIG18 is a perspective view of the optimized structure of the nickel catalyst (II-1) in one embodiment of the present disclosure; and

图19为本公开一实施例中镍催化剂(II-2)的优化结构立体图。FIG. 19 is a three-dimensional diagram of the optimized structure of the nickel catalyst (II-2) in one embodiment of the present disclosure.

具体实施方式DETAILED DESCRIPTION

为使本公开的目的、技术方案和优点更加清楚明白,以下结合具体实施例,并参照附图,对本公开作进一步的详细说明。In order to make the objectives, technical solutions and advantages of the present disclosure more clearly understood, the present disclosure is further described in detail below in combination with specific embodiments and with reference to the accompanying drawings.

在本公开中所公开的范围的端点和任何值都不限于该精确的范围或值,这些范围或值应当理解为包含接近这些范围或值的值。对于数值范围来说,各个范围的端点值之间、各个范围的端点值和单独的点值之间,以及单独的点值之间可以彼此组合而得到一个或多个新的数值范围,这些数值范围应被视为在本公开中具体公开。The endpoints and any values of the ranges disclosed in this disclosure are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values. For numerical ranges, the endpoint values of each range, the endpoint values of each range and the individual point values, and the individual point values can be combined with each other to obtain one or more new numerical ranges, and these numerical ranges should be regarded as specifically disclosed in this disclosure.

在此使用的术语仅仅是为了描述具体实施例,而并非意在限制本公开。在此使用的术语“包括”、“包含”等表明了所述特征、步骤、操作和/或部件的存在,但是并不排除存在或添加一个或多个其他特征、步骤、操作或部件。The terms used herein are only for describing specific embodiments and are not intended to limit the present disclosure. The terms "include", "comprising", etc. used herein indicate the existence of the features, steps, operations and/or components, but do not exclude the existence or addition of one or more other features, steps, operations or components.

在此使用的所有术语(包括技术和科学术语)具有本领域技术人员通常所理解的含义,除非另外定义。应注意,这里使用的术语应解释为具有与本说明书的上下文相一致的含义,而不应以理想化或过于刻板的方式来解释。All terms (including technical and scientific terms) used herein have the meanings commonly understood by those skilled in the art, unless otherwise defined. It should be noted that the terms used herein should be interpreted as having a meaning consistent with the context of this specification, and should not be interpreted in an idealized or overly rigid manner.

需要说明的是,除非另外定义,本公开使用的技术术语或者科学术语应当为本公开所属领域内具有一般技能的人士所理解的通常意义。若全文中涉及“第一”、“第二”等描述,则该“第一”、“第二”等描述仅用于区别类似的对象,而不能理解为指示或暗示其相对重要性、先后次序或者隐含指明所指示的技术特征的数量,应该理解为“第一”、“第二”等描述的数据在适当情况下可以互换。It should be noted that, unless otherwise defined, the technical terms or scientific terms used in the present disclosure shall have the usual meanings understood by persons with ordinary skills in the field to which the present disclosure belongs. If the full text involves descriptions such as "first", "second", etc., the descriptions such as "first", "second", etc. are only used to distinguish similar objects, and cannot be understood as indicating or implying their relative importance, order of precedence, or implicitly indicating the number of technical features indicated. It should be understood that the data described by "first", "second", etc. can be interchangeable under appropriate circumstances.

类似地,为了精简本公开并帮助理解各个公开方面中的一个或多个,在上面对本公开示例性实施例的描述中,本公开的各个特征有时被一起分到单个实施例、图或者对其描述中。参考术语“一个实施例”、“一些实施例”、“示例”、“具体示例”、或“一些示例”等的描述意指结合该实施例或示例描述的具体特征、结构、材料或者特点包含于本公开的至少一个实施例或示例中。本说明书中,对上述术语的示意性表述不一定指的是相同的实施例或示例。而且,描述的具体特征、结构、材料或者特点可以在任何的一个或者多个实施例或示例中以合适的方式结合。Similarly, in order to simplify the present disclosure and help understand one or more of the various disclosed aspects, in the above description of the exemplary embodiments of the present disclosure, the various features of the present disclosure are sometimes grouped together into a single embodiment, figure, or description thereof. The description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" and the like means that the specific features, structures, materials, or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present disclosure. In this specification, the schematic representation of the above terms does not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials, or characteristics described may be combined in any one or more embodiments or examples in a suitable manner.

另外,各个实施例之间的技术方案可以相互结合,但是必须是以本领域普通技术人员能够实现为基础,当技术方案的结合出现相互矛盾或无法实现时应当认为这种技术方案的结合不存在,也不在本公开要求的保护范围之内。In addition, the technical solutions between the various embodiments can be combined with each other, but it must be based on the fact that ordinary technicians in the field can implement it. When the combination of technical solutions is contradictory or cannot be implemented, it should be deemed that such combination of technical solutions does not exist and is not within the scope of protection required by this disclosure.

用于生产乙烯寡聚物的镍催化剂往往具有较强的β-H消除反应,因此通常在配体上安装空间位阻较小的基团或缺电子取代基。一些亚氨基镍催化剂可以通过不断重复的β-H消除反应和烯烃再插入构成链行走过程,产生高度支化的乙烯寡聚物。Nickel catalysts used to produce ethylene oligomers tend to have strong β-H elimination reactions, so sterically less hindered groups or electron-deficient substituents are usually installed on the ligands. Some imino nickel catalysts can produce highly branched ethylene oligomers through a chain walking process consisting of repeated β-H elimination reactions and olefin reinsertion.

在此基础上,我们合成了一系列具有噁唑结构的镍催化剂来生产超支化乙烯寡聚物。相比于位阻较大的苯胺等基团,噁唑环的空间位阻较小,有利于乙烯的插入,从而提高乙烯聚合活性。同时,空间位阻较小的噁唑环与空间位阻较大的苯胺可以形成不对称结构,有利于乙烯聚合过程中的链行走过程,从而产生高度支化的聚乙烯。On this basis, we synthesized a series of nickel catalysts with oxazole structures to produce hyperbranched ethylene oligomers. Compared with aniline and other groups with large steric hindrance, the oxazole ring has less steric hindrance, which is conducive to the insertion of ethylene, thereby improving the polymerization activity of ethylene. At the same time, the oxazole ring with less steric hindrance and the aniline with greater steric hindrance can form an asymmetric structure, which is conducive to the chain walking process during ethylene polymerization, thereby producing highly branched polyethylene.

本公开中提出的具有噁唑结构的镍催化剂在实际聚合中的催化机理如下式:The catalytic mechanism of the nickel catalyst with an oxazole structure proposed in the present disclosure in actual polymerization is as follows:

本领域技术人员周知,乙烯聚合过程主要包括链增长、链转移和链行走三步。在应用本公开中提出的具有噁唑结构的镍催化剂时,链增长过程是指乙烯与镍催化剂的金属中心配位、插入金属-烷基键;链转移过程是指在乙烯插入的过程中发生β-H消除,镍催化剂的金属中心空位与新的乙烯配位;链行走过程是指乙烯发生β-H消除后,翻转180°,重新与镍催化剂的金属中心配位、插入。It is well known to those skilled in the art that the ethylene polymerization process mainly includes three steps: chain growth, chain transfer and chain walking. When the nickel catalyst with an oxazole structure proposed in the present disclosure is used, the chain growth process refers to the coordination of ethylene with the metal center of the nickel catalyst and the insertion of the metal-alkyl bond; the chain transfer process refers to the β-H elimination that occurs during the ethylene insertion process, and the metal center vacancy of the nickel catalyst coordinates with new ethylene; the chain walking process refers to the β-H elimination of ethylene, the flipping of 180°, and the re-coordination and insertion with the metal center of the nickel catalyst.

本公开提出了一种具有噁唑结构的配体化合物,其结构如式(Ⅰ)所示,The present disclosure provides a ligand compound having an oxazole structure, the structure of which is shown in formula (I):

其中,R1选自甲基、二苯甲基中的任意一种;Wherein, R 1 is selected from any one of methyl and diphenylmethyl;

Ar选自萘基、苯并噻吩基、取代或未取代的苯中的一种,Ar is selected from naphthyl, benzothiophenyl, substituted or unsubstituted benzene,

当上述取代或未取代的苯具有取代基时,取代基选自吸电子取代基或供电子取代基。When the above-mentioned substituted or unsubstituted benzene has a substituent, the substituent is selected from an electron-withdrawing substituent or an electron-donating substituent.

根据本公开的实施例,具有噁唑结构的配体化合物的吸电子取代基选自三氟甲基、羟基、硝基中的任意一种,供电子取代基选自甲氧基。According to an embodiment of the present disclosure, the electron-withdrawing substituent of the ligand compound having an oxazole structure is selected from any one of trifluoromethyl, hydroxyl, and nitro, and the electron-donating substituent is selected from methoxy.

根据本公开的实施例,具有噁唑结构的配体化合物结构式如下式(Ⅰ-a)~(Ⅰ-c)中的任一所示:According to the embodiments of the present disclosure, the structural formula of the ligand compound having an oxazole structure is shown in any one of the following formulas (I-a) to (I-c):

其中,R2选自三氟甲基、羟基、硝基、甲氧基中的任意一种。Wherein, R2 is selected from any one of trifluoromethyl, hydroxyl, nitro, and methoxy.

在一些具体的实施例中,具有噁唑结构的配体化合物结构式如下所示:In some specific embodiments, the structural formula of the ligand compound having an oxazole structure is as follows:

在本公开的另一方面提出了一种制备上述的配体化合物的方法,包括:In another aspect of the present disclosure, a method for preparing the above-mentioned ligand compound is provided, comprising:

将如式(A)所示的化合物与酮酸甲酯类化合物反应,得到如式(B)所示的化合物;The compound represented by formula (A) is reacted with a keto acid methyl ester compound to obtain a compound represented by formula (B);

将如式(B)所示的化合物与2-氨基-2-甲基-1-丙醇反应,得到如式(C)所示的化合物;The compound represented by formula (B) is reacted with 2-amino-2-methyl-1-propanol to obtain a compound represented by formula (C);

使如式(C)所示的化合物进行自身异构化及脱水反应,得到如式(Ⅰ)所示的化合物。The compound represented by formula (C) is subjected to autoisomerization and dehydration reaction to obtain the compound represented by formula (I).

在一些具体的实施例中,酮酸甲酯类化合物包括以下结构:In some specific embodiments, the keto acid methyl ester compound comprises the following structure:

在一些具体的实施例中,化合物B的结构如下所示:In some specific embodiments, the structure of compound B is as follows:

在一些具体的实施例中,化合物C的结构如下所示:In some specific embodiments, the structure of compound C is shown below:

图1为本公开中具有噁唑结构的配体化合物的合成方法流程图。FIG1 is a flow chart of a method for synthesizing a ligand compound having an oxazole structure in the present disclosure.

根据本公开的实施例,如图1所示,制备上述的配体化合物的方法具体包括以下步骤S1~步骤S3:According to an embodiment of the present disclosure, as shown in FIG1 , the method for preparing the above-mentioned ligand compound specifically includes the following steps S1 to S3:

步骤S1:化合物(A)与酮酸甲酯类化合物以1:1的摩尔比混合,加入对甲苯磺酸一水合物在140℃~145℃下,分水回流反应40h,重结晶后得到化合物(B);Step S1: Compound (A) and keto acid methyl ester compound are mixed in a molar ratio of 1:1, p-toluenesulfonic acid monohydrate is added, and the mixture is refluxed at 140° C. to 145° C. for 40 h, and compound (B) is obtained after recrystallization;

步骤S2:化合物(B)与2-氨基-2-甲基-1-丙醇以1:2~1:2.5的摩尔比混合,在140℃~145℃下反应24h,分离得到化合物(C);Step S2: Compound (B) and 2-amino-2-methyl-1-propanol are mixed at a molar ratio of 1:2 to 1:2.5, reacted at 140° C. to 145° C. for 24 hours, and compound (C) is separated;

步骤S3:化合物(C)溶解后,加入三乙胺、4-二甲氨基吡啶、4-甲苯磺酰氯,在80℃~85℃下反应40h,得到配体化合物。Step S3: After compound (C) is dissolved, triethylamine, 4-dimethylaminopyridine and 4-toluenesulfonyl chloride are added and reacted at 80° C. to 85° C. for 40 hours to obtain a ligand compound.

根据本公开的实施例,三乙胺和4-二甲氨基吡啶在反应中作为催化剂而添加,4-甲苯磺酰氯属于醇类磺酰化试剂,可以促进二醇发生环氧化反应。According to the embodiments of the present disclosure, triethylamine and 4-dimethylaminopyridine are added as catalysts in the reaction, and 4-toluenesulfonyl chloride is an alcohol sulfonylating agent that can promote the epoxidation reaction of diols.

在本公开的另一方面提出了一种具有噁唑结构的镍催化剂,其结构如式(II)所示,In another aspect of the present disclosure, a nickel catalyst having an oxazole structure is provided, and its structure is shown in formula (II),

其中,R1选自甲基、二苯甲基中的任意一种;Wherein, R 1 is selected from any one of methyl and diphenylmethyl;

Ar选自萘基、苯并噻吩基、取代或未取代的苯中的一种,Ar is selected from naphthyl, benzothiophenyl, substituted or unsubstituted benzene,

上述取代或未取代的苯具有取代基时,该取代基选自吸电子取代基或供电子取代基;When the substituted or unsubstituted benzene has a substituent, the substituent is selected from an electron-withdrawing substituent or an electron-donating substituent;

其中,吸电子取代基优选为三氟甲基、羟基、硝基中的任意一种;Among them, the electron-withdrawing substituent is preferably any one of trifluoromethyl, hydroxyl, and nitro;

供电子取代基优选为甲氧基。The electron donating substituent is preferably a methoxy group.

根据本公开的实施例,当取代基Ar为供电子取代基时,镍金属中心的电子云密度增加,即增大了金属中心的亲核性,乙烯配位速率降低,所以得到活性较低的聚合物,同时催化剂的链行走能力与链转移能力降低,所以得到分子量较高的聚合物。According to the embodiments of the present disclosure, when the substituent Ar is an electron-donating substituent, the electron cloud density of the nickel metal center increases, that is, the nucleophilicity of the metal center is increased, and the ethylene coordination rate is reduced, so a polymer with lower activity is obtained. At the same time, the chain walking ability and chain transfer ability of the catalyst are reduced, so a polymer with higher molecular weight is obtained.

根据本公开的实施例,当取代基Ar为吸电子取代基时,镍金属中心的电子云密度降低,即增大了金属中心的亲电性,所得结果与取代基为供电子取代基时的结果相反,但是其支化度相对于取代基Ar为供电子取代基时高。According to an embodiment of the present disclosure, when the substituent Ar is an electron-withdrawing substituent, the electron cloud density of the nickel metal center is reduced, that is, the electrophilicity of the metal center is increased, and the result obtained is opposite to that when the substituent is an electron-donating substituent, but its branching degree is higher than when the substituent Ar is an electron-donating substituent.

根据本公开的实施例,当取代基Ar为大位阻取代基时,金属中心的空间屏蔽作用增加,即增大了金属中心的空间位阻,聚合过程更不容易发生β-H消除反应,即降低了链行走效率,所以得到相对较低支化度的聚合物;同时也使得乙烯配位插入能垒增加,所得聚合物活性、分子量较低。According to the embodiments of the present disclosure, when the substituent Ar is a large steric hindrance substituent, the spatial shielding effect of the metal center is increased, that is, the spatial hindrance of the metal center is increased, and the β-H elimination reaction is less likely to occur during the polymerization process, that is, the chain walking efficiency is reduced, so a polymer with a relatively low degree of branching is obtained; at the same time, it also increases the energy barrier for ethylene coordination insertion, and the activity and molecular weight of the resulting polymer are lower.

根据本公开的实施例,本公开中通过具有噁唑结构的配体化合物从而合成一种新型具有噁唑结构的镍催化剂。相比于位阻较大的苯胺,噁唑环的空间位阻较小,有利于乙烯的插入,从而提高乙烯聚合活性。同时空间位阻较小的噁唑环与空间位阻较大的苯胺形成不对称结构,有利于乙烯聚合中的链行走过程,从而产生高度支化的聚乙烯。According to the embodiments of the present disclosure, a novel nickel catalyst having an oxazole structure is synthesized by using a ligand compound having an oxazole structure. Compared with aniline having a larger steric hindrance, the oxazole ring has a smaller steric hindrance, which is beneficial to the insertion of ethylene, thereby improving the ethylene polymerization activity. At the same time, the oxazole ring having a smaller steric hindrance forms an asymmetric structure with the aniline having a larger steric hindrance, which is beneficial to the chain walking process in ethylene polymerization, thereby producing highly branched polyethylene.

根据本公开的实施例,具有噁唑结构的镍催化剂结构式如下式(II-a)~(II-c)中的任一所示:According to an embodiment of the present disclosure, the structural formula of the nickel catalyst having an oxazole structure is shown in any one of the following formulas (II-a) to (II-c):

其中,R2包括三氟甲基、羟基、硝基、甲氧基中的任意一种。Wherein, R 2 includes any one of trifluoromethyl, hydroxyl, nitro, and methoxy.

在一些具体的实施例中,具有噁唑结构的镍催化剂结构式如下所示:In some specific embodiments, the nickel catalyst having an oxazole structure has the following structural formula:

图2为本公开实施例8中具有噁唑结构的镍催化剂(II-2)的单晶结构示意图。FIG2 is a schematic diagram of the single crystal structure of the nickel catalyst (II-2) having an oxazole structure in Example 8 of the present disclosure.

在一些具体的实施例中,如图2所示,直观反应出镍催化剂(II-2)结构的正确性,以及表明了化合物的空间结构,即原子的相对位置关系。In some specific embodiments, as shown in FIG. 2 , the correctness of the structure of the nickel catalyst (II-2) is intuitively reflected, and the spatial structure of the compound, ie, the relative position relationship of the atoms, is indicated.

在本公开的另一方面提出了一种制备上述的具有噁唑结构的镍催化剂的方法,包括:将上述具有噁唑结构的配体化合物溶解,与乙二醇二甲醚溴化镍反应,加入正己烷,搅拌过滤,得到镍催化剂。In another aspect of the present disclosure, a method for preparing the above-mentioned nickel catalyst having an oxazole structure is proposed, comprising: dissolving the above-mentioned ligand compound having an oxazole structure, reacting with ethylene glycol dimethyl ether nickel bromide, adding n-hexane, stirring and filtering, and obtaining a nickel catalyst.

在本公开的其他方面还提出了应用上述具有噁唑结构的镍催化剂制备聚烯烃的方法,包括采用上述具有噁唑结构的镍催化剂作为催化剂通过聚合反应制备聚烯烃。In other aspects of the present disclosure, a method for preparing polyolefin using the nickel catalyst having an oxazole structure is also proposed, which comprises preparing polyolefin by polymerization reaction using the nickel catalyst having an oxazole structure as a catalyst.

根据本公开的实施例,聚合反应包括均聚反应、共聚反应中的任意一种。According to an embodiment of the present disclosure, the polymerization reaction includes any one of a homopolymerization reaction and a copolymerization reaction.

在一些具体的实施例中,聚合反应包括烯烃的均聚反应,也包括烯烃与极性单体的共聚反应。其中,极性单体主要是长链极性单体。长链极性单体包括但不限于6-氯-1-己烯、10-十一烯酸。In some specific embodiments, the polymerization reaction includes homopolymerization of olefins and copolymerization of olefins with polar monomers. The polar monomers are mainly long-chain polar monomers. The long-chain polar monomers include but are not limited to 6-chloro-1-hexene and 10-undecenoic acid.

在一些具体的实施例中,应用本公开提出的具有噁唑结构的镍催化剂作为催化剂通过聚合反应制备聚烯烃可以得到支化度范围为60~130内的超支化乙烯寡聚物。In some specific embodiments, a hyperbranched ethylene oligomer with a branching degree ranging from 60 to 130 can be obtained by using the nickel catalyst with an oxazole structure proposed in the present disclosure as a catalyst to prepare polyolefins through a polymerization reaction.

需要说明的是,所描述的实施例仅仅是本公开一部分实施例,而不是全部的实施例。基于本公开中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的其他实施例,都属于本公开保护的范围。It should be noted that the described embodiments are only part of the embodiments of the present disclosure, rather than all of the embodiments. Based on the embodiments of the present disclosure, other embodiments obtained by ordinary technicians in the field without creative work are all within the scope of protection of the present disclosure.

实施例1Example 1

步骤S1:将2,4-二甲基-6-二苯甲基苯胺(5.7g,20mmol)(即化合物A-1)与苯甲酰甲酸甲酯(3.28g,20mmol)、PTSA(50mg)和甲苯(40mL)装入250mL茄形瓶中。将所得混合物搅拌并加热至140℃,然后将反应体系用分水器回流24h以除去水,冷却至室温。旋干溶剂,用200mL甲醇重结晶,并用甲醇(3×100mL)洗涤,得到黄色固体形式的中间产物(B-1)(8.1g,93%),其反应过程如下式所示:Step S1: 2,4-dimethyl-6-benzhydrylaniline (5.7 g, 20 mmol) (ie, compound A-1), methyl benzoylformate (3.28 g, 20 mmol), PTSA (50 mg) and toluene (40 mL) were placed in a 250 mL eggplant-shaped bottle. The resulting mixture was stirred and heated to 140 ° C, and then the reaction system was refluxed for 24 h with a water separator to remove water and cooled to room temperature. The solvent was spin-dried, recrystallized with 200 mL of methanol, and washed with methanol (3×100 mL) to obtain the intermediate product (B-1) (8.1 g, 93%) in the form of a yellow solid, and the reaction process is shown in the following formula:

对中间产物(B-1)的结构采用1H NMR谱、13C NMR谱进行表征,具体表征结果如图3A、图3B所示。The structure of the intermediate product (B-1) was characterized by 1 H NMR spectrum and 13 C NMR spectrum. The specific characterization results are shown in FIG. 3A and FIG. 3B .

1H:NMR(400MHz,CDCl3)δ7.70(m,2H),7.52-7.46(m,1H),7.41(m,2H),7.28(m,3H),7.23(d,J=11.6Hz,3H),7.20-7.05(m,6H),6.89(d,J=1.9Hz,1H),6.57(d,J=1.9Hz,1H),5.49(s,1H,CH),3.58(s,3H,CH3),2.20(s,3H,CH3),2.07(s,3H,CH3)。 1 H: NMR (400MHz, CDCl 3 ) δ7.70 (m, 2H), 7.52-7.46 (m, 1H), 7.41 (m, 2H), 7.28 (m, 3H), 7.23 (d, J = 11.6Hz ,3H),7.20-7.05(m,6H),6.89(d,J=1.9Hz,1H),6.57(d,J=1.9Hz,1H),5.49(s,1H,CH),3.58(s, 3H,CH 3 ), 2.20 (s, 3H, CH 3 ), 2.07 (s, 3H, CH 3 ).

13C:NMR(101MHz,CDCl3)δ165.11(s),160.21(s),145.27(s),133.61(s),132.62(s),132.40(s),131.80(s),129.88(s),129.58(s),129.27(s),128.70(s),128.16(s),128.08(s),127.66(s),126.13(s),125.86(s),51.95(s),51.88(s),21.17(s),18.25(s)。 13 C: NMR (101MHz, CDCl 3 ) δ165.11(s), 160.21(s), 145.27(s), 133.61(s), 132.62(s), 132.40(s), 131.80(s), 129.88(s) ),129.58(s),129.27(s),128.70(s),128.16(s),128.08(s),127.66(s),126.13(s),125.86(s),51.95(s),51.88(s) ),21.17(s),18.25(s).

步骤S2:向350mL密封瓶中加入步骤S1制备得到的中间产物(B-1)(8.6g,19.8mmol)、2-氨基-2-甲基-1-丙醇(3.52g,39.6mmol)和甲醇(60mL)。将所得混合物搅拌并加热至140℃,回流40h,冷却至室温。旋干溶剂,柱层析分离得到黄色固体中间产物(C-1)(4.9g,50%)。Step S2: Add the intermediate product (B-1) (8.6 g, 19.8 mmol), 2-amino-2-methyl-1-propanol (3.52 g, 39.6 mmol) and methanol (60 mL) prepared in step S1 into a 350 mL sealed bottle. Stir and heat the resulting mixture to 140° C., reflux for 40 h, and cool to room temperature. The solvent is spin-dried and separated by column chromatography to obtain a yellow solid intermediate product (C-1) (4.9 g, 50%).

步骤S3:将中间产物(C-1)(2.5g,5mmol)、4-二甲氨基吡啶(DMAP)(0.73g,6mmol)、三乙胺(5mL)和二氯甲烷(20mL)装入350mL密封瓶中,置于0℃,向混合物中加入4-甲苯磺酰氯(TsCl)(1.14g,6mmol),搅拌2h后,将混合物置于80℃下搅拌40h。用饱和NaCl水溶液和DCM萃取溶液,收集有机相,旋干溶剂,柱层析分离得到黄色固体为式(Ⅰ-1)所示化合物(2.2g,95%)。Step S3: The intermediate product (C-1) (2.5 g, 5 mmol), 4-dimethylaminopyridine (DMAP) (0.73 g, 6 mmol), triethylamine (5 mL) and dichloromethane (20 mL) were placed in a 350 mL sealed bottle and placed at 0°C. 4-toluenesulfonyl chloride (TsCl) (1.14 g, 6 mmol) was added to the mixture and stirred for 2 h. The mixture was stirred at 80°C for 40 h. The solution was extracted with saturated NaCl aqueous solution and DCM, the organic phase was collected, the solvent was dried, and column chromatography was used to separate the yellow solid as the compound represented by formula (I-1) (2.2 g, 95%).

对化合物(Ⅰ-1)的结构采用1H NMR谱、13C NMR谱进行表征,具体表征结果如图4A、图4B所示。The structure of compound (I-1) was characterized by 1 H NMR spectrum and 13 C NMR spectrum. The specific characterization results are shown in Figures 4A and 4B.

1H NMR(400MHz,C6D6)δ8.27-8.18(m,2H),7.24-7.15(m,5H),7.11(m,2H),3.35(s,2H,CH2),3.22(d,J=6.8Hz,2H,CH),1.36(d,J=7.0Hz,6H,iPr),1.22(d,J=7.0Hz,6H,iPr),0.87(s,6H,CH3)。 1 H NMR (400MHz, C 6 D 6 ) δ8.27-8.18(m,2H),7.24-7.15(m,5H),7.11(m,2H),3.35(s,2H,CH 2 ),3.22( d,J=6.8Hz,2H,CH),1.36(d,J=7.0Hz,6H, iPr ),1.22(d,J=7.0Hz,6H, iPr ),0.87(s,6H,CH 3 ).

13C NMR(101MHz,C6D6)δ158.39(s),156.19(s),147.18(s),136.83(s),135.92(s),131.71(s),128.91(s),128.45(s),124.41(s),122.68(s),78.54(s),68.20(s),28.77(s),27.97(s),23.86(s),22.19(s)。 13 C NMR (101MHz, C 6 D 6 ) δ158.39(s), 156.19(s), 147.18(s), 136.83(s), 135.92(s), 131.71(s), 128.91(s), 128.45( s),124.41(s),122.68(s),78.54(s),68.20(s),28.77(s),27.97(s),23.86(s),22.19(s).

实施例2Example 2

化合物(Ⅰ-2)的合成路径如下式所示,The synthesis route of compound (I-2) is shown below:

步骤S1:将2,6-二二苯甲基-4-甲基苯胺(20mmol)(即化合物A-2)与苯甲酰甲酸甲酯(3.28g,20mmol)、PTSA(50mg)和甲苯(40mL)装入250mL茄形瓶中。将所得混合物搅拌并加热至140℃,然后将反应体系用分水器回流24h以除去水,冷却至室温。旋干溶剂,用200mL甲醇重结晶,并用甲醇(3×100mL)洗涤,得到黄色固体形式的中间产物(B-2)(10.8g,92%)。Step S1: 2,6-dibenzhydryl-4-methylaniline (20 mmol) (ie, compound A-2), methyl benzoylformate (3.28 g, 20 mmol), PTSA (50 mg) and toluene (40 mL) were placed in a 250 mL eggplant-shaped bottle. The resulting mixture was stirred and heated to 140 ° C, and then the reaction system was refluxed for 24 h with a water separator to remove water and cooled to room temperature. The solvent was spin-dried, recrystallized with 200 mL of methanol, and washed with methanol (3×100 mL) to obtain the intermediate product (B-2) (10.8 g, 92%) in the form of a yellow solid.

对中间产物(B-2)的结构采用1H NMR谱、13C NMR谱进行表征,具体表征结果如图5A、图5B所示。The structure of the intermediate product (B-2) was characterized by 1 H NMR spectrum and 13 C NMR spectrum. The specific characterization results are shown in FIG. 5A and FIG. 5B .

1H NMR(400MHz,C6D6)δ7.59-7.55(m,2H),7.39(d,J=7.6Hz,4H),7.10-7.08(m,2H),7.05(d,J=4.2Hz,12H),7.02-6.96(m,5H),6.95(s,2H),5.85(s,2H,CH),3.11(s,3H,CH3),1.88(s,3H,CH3)。 1 H NMR (400MHz, C 6 D 6 ) δ7.59-7.55(m,2H),7.39(d,J=7.6Hz,4H),7.10-7.08(m,2H),7.05(d,J=4.2 Hz,12H),7.02-6.96(m,5H),6.95(s,2H),5.85(s,2H,CH),3.11(s,3H,CH 3 ),1.88(s,3H,CH 3 ).

13C NMR(101MHz,C6D6)δ164.91(s),159.30(s),145.50(s),143.95(s),143.11(s),142.95(s),133.56(s),132.59(s),132.55(s),131.51(s),130.16(s),129.66(s),129.49(s),129.28(s),129.24(s),128.70(s),128.42(s),128.35(s),128.21(s),128.16(s),126.49(s),126.15(s),126.01(s),52.06(s),51.31(s),20.85(s)。 13 C NMR (101 MHz, C 6 D 6 )δ164.91(s),159.30(s),145.50(s),143.95(s),143.11(s),142.95(s),133.56(s),132.59(s),132.55(s),131.51(s),130.16(s),129.66(s), 129.49(s),129.28(s),129.24(s),128.70(s),128.42(s),128.35(s),128.21(s),128.16(s),126.49(s),126.15(s),126.01(s),52.06(s),51 .31(s),20.85(s).

步骤S2同实施例1中的步骤S2,其中,中间产物(C-2)的产量为5.7g,产率为45%。Step S2 is the same as step S2 in Example 1, wherein the output of the intermediate product (C-2) is 5.7 g, and the yield is 45%.

对中间产物(C-2)的结构采用1H NMR谱、13C NMR谱进行表征,具体表征结果如图6A、图6B所示。The structure of the intermediate product (C-2) was characterized by 1 H NMR spectrum and 13 C NMR spectrum. The specific characterization results are shown in FIG6A and FIG6B .

1H NMR(400MHz,C6D6)δ7.49-7.45(m,2H),7.17(d,J=7.3Hz,6H),7.14(s,3H),7.12(d,J=1.7Hz,3H),7.10-7.03(m,7H),6.98(d,J=7.5Hz,3H),6.83(s,2H),6.72(s,1H),5.37(s,2H,CH2),4.70-4.60(m,1H,NH),3.71(d,J=5.2Hz,2H,CH),1.87(s,3H,CH3),1.09(s,6H,CH3)。 1 H NMR (400MHz, C 6 D 6 ) δ7.49-7.45 (m, 2H), 7.17 (d, J = 7.3Hz, 6H), 7.14 (s, 3H), 7.12 (d, J = 1.7Hz, 3H),7.10-7.03(m,7H),6.98(d,J=7.5Hz,3H),6.83(s,2H),6.72(s,1H),5.37(s,2H,CH 2 ),4.70- 4.60 (m, 1H, NH), 3.71 (d, J = 5.2Hz, 2H, CH), 1.87 (s, 3H, CH 3 ), 1.09 (s, 6H, CH 3 ).

13C NMR(101MHz,C6D6)δ163.73(s),159.82(s),142.96(s),142.94(s),133.64(s),132.68(s),132.13(s),130.50(s),130.22(s),129.77(s),129.56(s),129.38(s),128.73(s),128.51(s),126.80(s),126.54(s),70.63(s),55.87(s),53.08(s),24.26(s),21.11(s)。 13 C NMR (101MHz, C 6 D 6 ) δ163.73(s), 159.82(s), 142.96(s), 142.94(s), 133.64(s), 132.68(s), 132.13(s), 130.50( s),130.22(s),129.77(s),129.56(s),129.38(s),128.73(s),128.51(s),126.80(s),126.54(s),70.63(s),55.87( s),53.08(s),24.26(s),21.11(s).

步骤S3同实施例1中的步骤S3,其中,化合物(Ⅰ-2)的产量为2.8g,产率为90%。Step S3 is the same as step S3 in Example 1, wherein the yield of compound (I-2) is 2.8 g, and the yield rate is 90%.

对化合物(Ⅰ-2)的结构采用1H NMR谱、13C NMR谱进行表征,具体表征结果如图7A、图7B所示。The structure of compound (I-2) was characterized by 1 H NMR spectrum and 13 C NMR spectrum. The specific characterization results are shown in Figures 7A and 7B.

1H NMR(400MHz,C6D6)δ7.82-7.77(m,2H),7.59(d,J=7.6Hz,4H),7.33(m,4H),7.28(s,3H),7.24-7.17(m,10H),7.14-7.12(m,2H),7.04(s,2H),6.01(s,2H,CH2),3.56(s,2H,CH),2.04(s,3H,CH3),1.13(s,6H,CH3)。 1 H NMR (400MHz, C 6 D 6 ) δ7.82-7.77(m,2H),7.59(d,J=7.6Hz,4H),7.33(m,4H),7.28(s,3H),7.24- 7.17(m,10H),7.14-7.12(m,2H),7.04(s,2H),6.01(s,2H,CH 2 ),3.56(s,2H,CH),2.04(s,3H,CH 3 ),1.13(s,6H,CH 3 ).

13C NMR(101MHz,C6D6)δ157.22(s),156.60(s),146.49(s),144.66(s),143.46(s),143.36(s),135.49(s),132.62(s),132.20(s),131.60(s),130.68(s),130.01(s),129.86(s),129.63(s),129.59(s),128.77(s),128.45(s),128.39(s),128.16(s),126.84(s),126.42(s),126.21(s),78.64(s),68.46(s),52.51(s),28.19(s),21.29(s)。 13 C NMR (101 MHz, C 6 D 6 )δ157.22(s),156.60(s),146.49(s),144.66(s),143.46(s),143.36(s),135.49(s),132.62(s),132.20(s),131.60(s),130.68(s),130.01(s), 129.86(s),129.63(s),129.59(s),128.77(s),128.45(s),128.39(s),128.16(s),126.84(s),126.42(s),126.21(s),78.64(s),68.46(s),52.5 1(s),28.19(s),21.29(s).

实施例3Example 3

化合物(Ⅰ-3)的合成路径如下式所示:The synthesis route of compound (I-3) is shown below:

其中,实施例3的制备方法与实施例1中相同,反应物由苯甲酰甲酸甲酯替换为2-(4-甲氧基苯基)-2-氧代乙酸甲酯。The preparation method of Example 3 is the same as that of Example 1, and the reactant is replaced by methyl benzoylformate with methyl 2-(4-methoxyphenyl)-2-oxoacetate.

中间产物(B-3)的产量为11.4g,产率为93%。对中间产物(B-3)的结构采用1H NMR谱、13C NMR谱进行表征,具体表征结果如图8A、图8B所示。The yield of the intermediate product (B-3) was 11.4 g, with a yield of 93%. The structure of the intermediate product (B-3) was characterized by 1 H NMR spectrum and 13 C NMR spectrum, and the specific characterization results are shown in FIG8A and FIG8B .

1H NMR(400MHz,CDCl3)δ7.44(d,J=8.4Hz,2H),7.36-7.27(m,6H),7.21(d,J=7.0Hz,10H),7.00(d,J=6.9Hz,4H),6.90(d,J=8.5Hz,2H),6.67(s,2H),5.53(s,2H,CH),3.86(s,3H,CH3),3.57(s,3H,CH3),2.20(s,3H,CH3)。 1 H NMR (400MHz, CDCl 3 ) δ7.44 (d, J=8.4Hz, 2H), 7.36-7.27 (m, 6H), 7.21 (d, J=7.0Hz, 10H), 7.00 (d, J= 6.9Hz,4H),6.90(d,J=8.5Hz,2H),6.67(s,2H),5.53(s,2H,CH),3.86(s,3H,CH 3 ),3.57(s,3H, CH 3 ),2.20(s,3H,CH 3 ).

13C NMR(101MHz,CDCl3)δ164.89(s),162.41(s),157.96(s),145.23(s),143.66(s),143.18(s),132.18(s),131.98(s),130.07(s),129.99(s),129.41(s),128.38(s),128.16(s),127.89(s),126.09(s),125.89(s),113.80(s),51.93(s),21.48(s)。 13 C NMR (101MHz, CDCl 3 ) δ164.89(s), 162.41(s), 157.96(s), 145.23(s), 143.66(s), 143.18(s), 132.18(s), 131.98(s) ,130.07(s),129.99(s),129.41(s),128.38(s),128.16(s),127.89(s),126.09(s),125.89(s),113.80(s),51.93(s) ,21.48(s).

中间产物(C-3)的产量为6.5g,产率为49%。对其结构采用1H NMR谱、13C NMR谱进行表征,具体表征结果如图9A、图9B所示。The yield of the intermediate product (C-3) was 6.5 g, with a yield of 49%. Its structure was characterized by 1 H NMR spectrum and 13 C NMR spectrum, and the specific characterization results are shown in Figures 9A and 9B.

1H NMR(400MHz,C6D6)δ7.45-7.42(m,2H),7.06(m,11H),7.00-6.92(m,8H),6.80(s,2H),6.70(s,1H),6.59-6.53(m,2H,CH2),5.34(s,2H,CH),3.65(s,1H,NH),3.15(s,3H,CH3),1.82(s,3H,CH3),1.01(s,6H,CH3)。 1 H NMR (400MHz, C 6 D 6 ) δ7.45-7.42(m,2H),7.06(m,11H),7.00-6.92(m,8H),6.80(s,2H),6.70(s,1H ),6.59-6.53(m,2H,CH 2 ),5.34(s,2H,CH),3.65(s,1H,NH),3.15(s,3H,CH 3 ),1.82(s,3H,CH 3 ),1.01(s,6H,CH 3 ).

13C NMR(101MHz,C6D6)δ164.23(s),161.82(s),159.21(s),143.89(s),143.09(s),133.38(s),132.17(s),131.94(s),130.27(s),129.57(s),129.47(s),128.71(s),128.52(s),126.76(s),126.52(s),124.98(s),113.71(s),70.78(s),55.88(s),54.86(s),53.09(s),24.30(s),21.15(s)。 13 C NMR (101MHz, C 6 D 6 ) δ164.23(s), 161.82(s), 159.21(s), 143.89(s), 143.09(s), 133.38(s), 132.17(s), 131.94( s),130.27(s),129.57(s),129.47(s),128.71(s),128.52(s),126.76(s),126.52(s),124.98(s),113.71(s),70.78( s),55.88(s),54.86(s),53.09(s),24.30(s),21.15(s).

化合物(Ⅰ-3)的产量3.0g,产率为92%。对其结构采用1H NMR谱、13C NMR谱进行表征,具体表征结果如图10A、图10B所示。The yield of compound (I-3) was 3.0 g, with a yield of 92%. Its structure was characterized by 1 H NMR spectrum and 13 C NMR spectrum, and the specific characterization results are shown in Figures 10A and 10B.

1H NMR(400MHz,C6D6)δ7.70(d,J=8.4Hz,2H),7.57(d,J=7.6Hz,4H),7.30(m,4H),7.24(s,1H),7.17(d,J=7.5Hz,5H),7.13(d,J=17.1Hz,6H),6.99(s,2H),6.69(d,J=8.4Hz,2H),6.00(s,2H,CH2),4.39(s,1H,CH),3.58(s,1H,CH),3.25(s,3H,CH3),2.01(s,3H,CH3),1.13(s,6H,CH3)。 1 H NMR (400MHz, C 6 D 6 ) δ7.70 (d, J = 8.4 Hz, 2H), 7.57 (d, J = 7.6 Hz, 4H), 7.30 (m, 4H), 7.24 (s, 1H) ,7.17(d,J=7.5Hz,5H),7.13(d,J=17.1Hz,6H),6.99(s,2H),6.69(d,J=8.4Hz,2H),6.00(s,2H, CH 2 ),4.39(s,1H,CH),3.58(s,1H,CH),3.25(s,3H,CH 3 ),2.01(s,3H,CH 3 ),1.13(s,6H,CH 3 ).

13C NMR(101MHz,C6D6)δ162.83(s),156.87(s),156.28(s),146.63(s),144.79(s),143.47(s),132.88(s),131.94(s),130.69(s),130.52(s),129.87(s),128.45(s),126.41(s),126.15(s),113.94(s),78.63(s),68.46(s),54.84(s),53.41(s),52.53(s),28.26(s),21.34(s)。 13 C NMR (101MHz, C 6 D 6 ) δ162.83(s), 156.87(s), 156.28(s), 146.63(s), 144.79(s), 143.47(s), 132.88(s), 131.94( s),130.69(s),130.52(s),129.87(s),128.45(s),126.41(s),126.15(s),113.94(s),78.63(s),68.46(s),54.84( s),53.41(s),52.53(s),28.26(s),21.34(s).

实施例4Example 4

化合物(Ⅰ-4)的合成路径如下式所示:The synthesis route of compound (I-4) is shown below:

其中,实施例4的制备方法与实施例1中相同,反应物由苯甲酰甲酸甲酯替换为2-(4-三氟甲基苯基)-2-氧代乙酸甲酯。The preparation method of Example 4 is the same as that of Example 1, and the reactant is replaced by methyl benzoylformate with methyl 2-(4-trifluoromethylphenyl)-2-oxoacetate.

中间产物(B-4)的产量为11.9g,产率为91%。对其结构采用1H NMR谱、13C NMR谱进行表征,具体表征结果如图11A、图11B所示。The yield of the intermediate product (B-4) was 11.9 g, with a yield of 91%. Its structure was characterized by 1 H NMR spectrum and 13 C NMR spectrum, and the specific characterization results are shown in Figures 11A and 11B.

1H NMR(400MHz,CDCl3)δ7.68(d,J=8.0Hz,2H),7.56(d,J=8.2Hz,2H),7.37(m,5H),7.31(m,6H),7.20(d,J=7.6Hz,5H),7.05-6.96(m,4H),6.69(s,2H),5.47(s,2H,CH),3.62(s,3H,CH3),2.23(s,3H,CH3)。 1 H NMR (400MHz, CDCl 3 ) δ7.68 (d, J = 8.0 Hz, 2H), 7.56 (d, J = 8.2 Hz, 2H), 7.37 (m, 5H), 7.31 (m, 6H), 7.20 (d,J=7.6Hz,5H),7.05-6.96(m,4H),6.69(s,2H),5.47(s,2H,CH),3.62(s,3H,CH 3 ),2.23(s, 3H,CH 3 ).

13C NMR(101MHz,CDCl3)δ163.63(s),157.64(s),144.76(s),143.27(s),142.95(s),136.89(s),132.67(s),131.55(s),129.99(s),129.41(s),128.68(s),128.57(s),128.30(s),128.05(s),126.82(s),126.31(s),126.12(s),125.39(s),51.97(s),21.51(s)。 13 C NMR (101MHz, CDCl 3 ) δ163.63(s), 157.64(s), 144.76(s), 143.27(s), 142.95(s), 136.89(s), 132.67(s), 131.55(s) ,129.99(s),129.41(s),128.68(s),128.57(s),128.30(s),128.05(s),126.82(s),126.31(s),126.12(s),125.39(s) ,51.97(s),21.51(s).

中间产物(C-4)的产量为7.5g,产率为53%。对其结构采用1H NMR谱、13C NMR谱进行表征,具体表征结果如图12A、图12B所示。The yield of the intermediate product (C-4) was 7.5 g, with a yield of 53%. Its structure was characterized by 1 H NMR spectrum and 13 C NMR spectrum, and the specific characterization results are shown in Figures 12A and 12B.

1H NMR(400MHz,C6D6)δ7.26(s,5H),7.18(s,4H),7.14(s,4H),7.13-7.04(m,6H),6.91(d,J=7.2Hz,5H),6.87(s,2H),5.29(s,2H,CH2),4.23(d,J=5.9Hz,1H,NH),3.69(d,J=4.5Hz,2H,CH),1.89(s,3H,CH3),1.13(s,6H,CH3)。 1 H NMR (400MHz, C 6 D 6 ) δ7.26 (s, 5H), 7.18 (s, 4H), 7.14 (s, 4H), 7.13-7.04 (m, 6H), 6.91 (d, J = 7.2 Hz,5H),6.87(s,2H),5.29(s,2H,CH 2 ),4.23(d,J=5.9Hz,1H,NH),3.69(d,J=4.5Hz,2H,CH), 1.89(s,3H,CH 3 ), 1.13(s,6H,CH 3 ).

13C NMR(101MHz,C6D6)δ162.69(s),158.78(s),142.55(s),142.39(s),141.97(s),135.34(s),133.96(s),131.87(s),130.10(s),129.78(s),129.65(s),129.23(s),129.18(s),128.85(s),128.45(s),128.25(s),126.67(s),126.34(s),124.74(s),124.70(s),69.90(s),55.56(s),52.66(s),23.82(s),20.70(s)。 13 C NMR (101MHz, C 6 D 6 ) δ162.69(s),158.78(s),142.55(s),142.39(s),141.97(s),135.34(s),133.96(s),131.87( s),130.10(s),129.78(s),129.65(s),129.23(s),129.18(s),128.85(s),128.45(s),128.25(s),126.67(s),126.34( s),124.74(s),124.70(s),69.90(s),55.56(s),52.66(s),23.82(s),20.70(s).

化合物(Ⅰ-4)的产量为3.2g,产率为92%。对其结构采用1H NMR谱、13C NMR谱进行表征,具体表征结果如图13A、图13B所示。The yield of compound (I-4) was 3.2 g, with a yield of 92%. Its structure was characterized by 1 H NMR spectrum and 13 C NMR spectrum, and the specific characterization results are shown in Figures 13A and 13B.

1H NMR(400MHz,C6D6)δ7.66(d,J=8.1Hz,2H),7.56(d,J=7.6Hz,4H),7.36(m,6H),7.30(s,1H),7.27-7.17(m,6H),7.14(d,J=4.7Hz,5H),7.04(s,2H),5.91(s,2H,CH2),3.58(s,2H,CH),2.04(s,3H,CH3),1.16(s,6H,CH3)。 1 H NMR (400MHz, C 6 D 6 ) δ7.66 (d, J = 8.1 Hz, 2H), 7.56 (d, J = 7.6 Hz, 4H), 7.36 (m, 6H), 7.30 (s, 1H) ,7.27-7.17(m,6H),7.14(d,J=4.7Hz,5H),7.04(s,2H),5.91(s,2H,CH 2 ),3.58(s,2H,CH),2.04( s,3H,CH 3 ),1.16(s,6H,CH 3 ).

13C NMR(101MHz,C6D6)δ156.08(s),146.11(s),144.29(s),143.16(s),138.61(s),132.64(s),132.11(s),130.58(s),129.77(s),129.19(s),128.54(s),128.49(s),126.59(s),126.37(s),125.33(s),125.29(s),125.26(s),78.75(s),68.51(s),52.55(s),28.14(s),21.27(s)。 13 C NMR (101MHz, C 6 D 6 ) δ156.08(s),146.11(s),144.29(s),143.16(s),138.61(s),132.64(s),132.11(s),130.58( s),129.77(s),129.19(s),128.54(s),128.49(s),126.59(s),126.37(s),125.33(s),125.29(s),125.26(s),78.75( s),68.51(s),52.55(s),28.14(s),21.27(s).

实施例5Example 5

化合物(Ⅰ-5)的合成路径如下式所示:The synthesis route of compound (I-5) is shown below:

其中,实施例5的制备方法与实施例1中相同,反应物由苯甲酰甲酸甲酯替换为2-(萘-2-基)-2-氧代乙酸甲酯。The preparation method of Example 5 is the same as that of Example 1, and the reactant is replaced by methyl benzoylformate with methyl 2-(naphthalene-2-yl)-2-oxoacetate.

中间产物(B-5)的产量为11.5g,产率为90%。对中间产物(B-5)的结构采用1H NMR谱、13C NMR谱进行表征,具体表征结果如图14A、图14B所示。The yield of the intermediate product (B-5) was 11.5 g, with a yield of 90%. The structure of the intermediate product (B-5) was characterized by 1 H NMR spectrum and 13 C NMR spectrum, and the specific characterization results are shown in Figures 14A and 14B.

1H NMR(400MHz,CDCl3)δ7.87(m,3H),7.76(d,J=8.7Hz,1H),7.54(m,3H),7.32-7.28(m,4H),7.25-7.13(m,12H),7.00-6.92(m,4H),6.65(d,J=3.1Hz,2H),5.51(d,J=3.4Hz,2H,CH),3.71-3.53(m,3H,CH3),2.18(d,J=2.3Hz,3H,CH3)。 1 H NMR (400MHz, CDCl 3 ) δ7.87 (m, 3H), 7.76 (d, J = 8.7Hz, 1H), 7.54 (m, 3H), 7.32-7.28 (m, 4H), 7.25-7.13 ( m,12H),7.00-6.92(m,4H),6.65(d,J=3.1Hz,2H),5.51(d,J=3.4Hz,2H,CH),3.71-3.53(m,3H,CH 3 ), 2.18 (d, J = 2.3Hz, 3H, CH 3 ).

13C NMR(101MHz,CDCl3)δ164.74(s),158.86(s),145.21(s),143.55(s),143.16(s),135.02(s),132.69(s),132.27(s),131.98(s),131.12(s),130.04(s),129.73(s),129.49(s),129.23(s),128.48(s),128.23(s),127.99(s),127.90(s),126.62(s),126.17(s),125.97(s),124.25(s),52.20(s),51.93(s),21.54(s)。 13 C NMR (101MHz, CDCl 3 ) δ164.74(s), 158.86(s), 145.21(s), 143.55(s), 143.16(s), 135.02(s), 132.69(s), 132.27(s) ,131.98(s),131.12(s),130.04(s),129.73(s),129.49(s),129.23(s),128.48(s),128.23(s),127.99(s),127.90(s) ,126.62(s),126.17(s),125.97(s),124.25(s),52.20(s),51.93(s),21.54(s).

中间产物(C-5)的产量为6.6g,产率为48%。对其结构采用1H NMR谱、13C NMR谱进行表征,具体表征结果如图15A、图15B所示。The yield of the intermediate product (C-5) was 6.6 g, with a yield of 48%. Its structure was characterized by 1 H NMR spectrum and 13 C NMR spectrum, and the specific characterization results are shown in Figures 15A and 15B.

1H NMR(400MHz,C6D6)δ7.95(s,1H),7.48(d,J=7.6Hz,4H),7.40(d,J=9.5Hz,2H),7.20(m,2H),7.09(d,J=4.5Hz,9H),6.94(d,J=7.4Hz,3H),6.89(d,J=7.1Hz,2H),6.83(d,J=7.4Hz,5H),6.76(s,2H),5.39(s,2H,CH2),4.54(s,1H,NH),3.67(s,2H,CH),1.78(s,3H,CH3),1.05(s,6H,CH3)。 1 H NMR (400MHz, C 6 D 6 ) δ7.95 (s, 1H), 7.48 (d, J = 7.6Hz, 4H), 7.40 (d, J = 9.5Hz, 2H), 7.20 (m, 2H) ,7.09(d,J=4.5Hz,9H),6.94(d,J=7.4Hz,3H),6.89(d,J=7.1Hz,2H),6.83(d,J=7.4Hz,5H),6.76 (s,2H),5.39(s,2H,CH 2 ),4.54(s,1H,NH),3.67(s,2H,CH),1.78(s,3H,CH 3 ),1.05(s,6H, CH 3 ).

13C NMR(101MHz,C6D6)δ163.88(s),160.14(s),143.64(s),143.10(s),142.84(s),134.27(s),133.68(s),132.84(s),132.27(s),130.78(s),130.56(s),130.12(s),129.63(s),129.40(s),129.34(s),129.17(s),128.69(s),128.56(s),126.74(s),126.62(s),126.57(s),126.15(s),70.66(s),55.97(s),53.10(s),24.34(s),21.11(s)。 13 C NMR (101 MHz, C 6 D 6 )δ163.88(s),160.14(s),143.64(s),143.10(s),142.84(s),134.27(s),133.68(s),132.84(s),132.27(s),130.78(s),130.56(s),130.12(s), 129.63(s),129.40(s),129.34(s),129.17(s),128.69(s),128.56(s),126.74(s),126.62(s),126.57(s),126.15(s),70.66(s),55.97(s),53.1 0(s),24.34(s),21.11(s).

化合物(Ⅰ-5)的产量3.1g,产率为92%。对其结构采用1H NMR谱、13C NMR谱进行表征,具体表征结果如图16A、图16B所示。The yield of compound (I-5) was 3.1 g, with a yield of 92%. Its structure was characterized by 1 H NMR spectrum and 13 C NMR spectrum, and the specific characterization results are shown in Figures 16A and 16B.

1H NMR(400MHz,C6D6)δ8.20(s,1H),7.72-7.66(m,1H),7.65-7.58(m,1H),7.48(m,6H),7.22(m,6H),7.08(m,12H),6.95(s,2H),5.95(s,2H,CH2),3.51(s,2H,CH),1.94(s,3H,CH3),1.08(s,6H,CH3)。 1 H NMR (400MHz, C 6 D 6 ) δ8.20(s,1H),7.72-7.66(m,1H),7.65-7.58(m,1H),7.48(m,6H),7.22(m,6H ),7.08(m,12H),6.95(s,2H),5.95(s,2H,CH 2 ),3.51(s,2H,CH),1.94(s,3H,CH 3 ),1.08(s,6H , CH 3 ).

13C NMR(101MHz,C6D6)δ157.14(s),156.74(s),146.56(s),144.63(s),143.36(s),135.43(s),133.19(s),133.13(s),132.63(s),132.22(s),130.68(s),130.22(s),129.91(s),129.43(s),128.49(s),126.46(s),126.21(s),124.92(s),78.71(s),68.57(s),52.62(s),28.26(s),21.33(s)。 13 C NMR (101MHz, C 6 D 6 ) δ157.14(s), 156.74(s), 146.56(s), 144.63(s), 143.36(s), 135.43(s), 133.19(s), 133.13( s),132.63(s),132.22(s),130.68(s),130.22(s),129.91(s),129.43(s),128.49(s),126.46(s),126.21(s),124.92( s),78.71(s),68.57(s),52.62(s),28.26(s),21.33(s).

实施例6Example 6

化合物(Ⅰ-6)的合成路径如下式所示:The synthesis route of compound (I-6) is shown below:

在氮气氛围下,在200mL Schlenk瓶中加入化合物(Ⅰ-3)(0.49g,0.74mmol)和二氯甲烷(10mL),0℃下将BBr3(7.5mL,1mmol/mL)逐滴加入混合物中,搅拌2h后加热至20℃搅拌12h。0℃下用饱和NaCl水溶液淬灭BBr3,并用DCM萃取,收集有机相,旋干溶剂,柱层析分离得到黄色固体为化合物(Ⅰ-6)(0.28g,59%)。Under nitrogen atmosphere, compound (I-3) (0.49 g, 0.74 mmol) and dichloromethane (10 mL) were added to a 200 mL Schlenk bottle, and BBr 3 (7.5 mL, 1 mmol/mL) was added dropwise to the mixture at 0°C. After stirring for 2 h, the mixture was heated to 20°C and stirred for 12 h. BBr 3 was quenched with saturated aqueous NaCl solution at 0°C, and extracted with DCM. The organic phase was collected, the solvent was dried, and the yellow solid was separated by column chromatography to obtain compound (I-6) (0.28 g, 59%).

对化合物(Ⅰ-6)的结构采用1H NMR谱、13C NMR谱进行表征,具体表征结果如图17A、图17B所示。The structure of compound (I-6) was characterized by 1 H NMR spectrum and 13 C NMR spectrum. The specific characterization results are shown in Figures 17A and 17B.

1H NMR(400MHz,C6D6)δ7.10(m,1.8Hz,10H),7.00(m,11H),6.83(s,2H),6.65(s,1H),6.39–6.36(m,2H),5.49(s,2H),3.60(s,2H),1.82(s,3H),1.06(s,7H)。 1 H NMR (400MHz, C 6 D 6 ) δ7.10 (m, 1.8Hz, 10H), 7.00 (m, 11H), 6.83 (s, 2H), 6.65 (s, 1H), 6.39–6.36 (m, 2H),5.49(s,2H),3.60(s,2H),1.82(s,3H),1.06(s,7H).

13C NMR(101MHz,DMSO)δ173.71(s),161.36(s),156.63(s),156.26(s),145.97(s),144.05(s),142.81(s),132.24(s),130.28(s),129.96(s),129.69(s),129.25(s),128.70(s),128.56(s),128.25(s),127.58(s),126.74(s),126.56(s),126.35(s),125.86(s),115.67(s),78.64(s),68.44(s),51.57(s),28.24(s),22.99(s),21.56(s)。 13 C NMR(101MHz,DMSO)δ173.71(s),161.36(s),156.63(s),156.26(s),145.97(s),144.05(s),142.81(s),132.24(s), 130.28(s),129.96(s),129.69(s),129.25(s),128 .70(s),128.56(s),128.25(s),127.58(s),126.74(s),126.56(s),126.35(s),125.86(s),115.67(s),78.64(s) ,68.44(s),51.57(s),28.24(s),22.99(s),21.56(s).

实施例7Example 7

镍催化剂(II-1)的合成路径如下式所示:The synthesis route of nickel catalyst (II-1) is shown below:

手套箱中,将化合物(Ⅰ-1)(0.47g,1.0mmol),加入20mL DCM和(DME)NiBr2(0.31g,1.0mmol)的混合溶液中,室温搅拌12h,将溶液在真空线上抽干,加入30mL正己烷搅拌15min,过滤得到暗红色固体为镍催化剂(II-1)(0.62g,90%)。In a glove box, compound (I-1) (0.47 g, 1.0 mmol) was added to a mixed solution of 20 mL DCM and (DME)NiBr 2 (0.31 g, 1.0 mmol), stirred at room temperature for 12 h, the solution was drained on a vacuum line, 30 mL of n-hexane was added, stirred for 15 min, and filtered to obtain a dark red solid as nickel catalyst (II-1) (0.62 g, 90%).

质谱分析的结果MALDI-TOF(m/z):计算值:C33H32Br2N2NiO:691.13,测试值:610.870[M-Br]+Results of mass spectrometry analysis: MALDI-TOF (m/z): calculated value: C 33 H 32 Br 2 N 2 NiO: 691.13, found value: 610.870 [M-Br] + .

实施例8Example 8

镍催化剂(II-2)的合成路径如下式所示:The synthesis route of nickel catalyst (II-2) is shown below:

镍催化剂(II-2)的合成方法如实施例7,其中,镍催化剂(II-2)的产量为0.62g,产率为74%。The synthesis method of nickel catalyst (II-2) is as shown in Example 7, wherein the output of nickel catalyst (II-2) is 0.62 g, and the yield is 74%.

质谱分析的结果MALDI-TOF(m/z):计算值C45H40Br2N2NiO:843.33,测试值:763.169[M-Br]+Results of mass spectrometry analysis: MALDI-TOF (m/z): calculated for C 45 H 40 Br 2 N 2 NiO: 843.33, found: 763.169 [M-Br] + .

实施例9Example 9

镍催化剂(II-3)的合成路径如下式所示:The synthesis route of nickel catalyst (II-3) is shown below:

镍催化剂(II-3)的合成方法如实施例7,其中,镍催化剂(II-3)的产量为0.75g,产率为86%。The synthesis method of nickel catalyst (II-3) is as shown in Example 7, wherein the output of nickel catalyst (II-3) is 0.75 g, and the yield is 86%.

质谱分析的结果MALDI-TOF(m/z):计算值C46H42Br2N2NiO2:873.36,测试值:793.083[M-Br]+Results of mass spectrometry analysis: MALDI-TOF (m/z): calculated for C 46 H 42 Br 2 N 2 NiO 2 : 873.36, found: 793.083 [M-Br] + .

实施例10Example 10

镍催化剂(II-4)的合成路径如下式所示:The synthesis route of nickel catalyst (II-4) is shown below:

镍催化剂(II-4)的合成方法如实施例7,其中,镍催化剂(II-4)的产量为0.76g,产率为83%。The synthesis method of nickel catalyst (II-4) is as shown in Example 7, wherein the output of nickel catalyst (II-4) is 0.76 g, and the yield is 83%.

质谱分析的结果MALDI-TOF(m/z):计算值C46H39Br2F3N2NiO:911.33,测试值:831.179[M-Br]+Results of mass spectrometry analysis: MALDI-TOF (m/z): calculated for C 46 H 39 Br 2 F 3 N 2 NiO: 911.33, found: 831.179 [M-Br] + .

实施例11Embodiment 11

镍催化剂(II-5)的合成路径如下式所示:The synthesis route of nickel catalyst (II-5) is shown below:

镍催化剂(II-5)的合成方法如实施例7,其中,镍催化剂(II-5)的产量为0.68g,产率为83%。The synthesis method of nickel catalyst (II-5) is as shown in Example 7, wherein the output of nickel catalyst (II-5) is 0.68 g, and the yield is 83%.

质谱分析的结果MALDI-TOF(m/z):计算值C49H42Br2N2NiO:893.39,测试值:813.217[M-Br]+Results of mass spectrometry analysis: MALDI-TOF (m/z): calculated for C 49 H 42 Br 2 N 2 NiO: 893.39, found: 813.217 [M-Br] + .

实施例12Example 12

镍催化剂(II-6)的合成路径如下式所示:The synthesis route of nickel catalyst (II-6) is shown below:

镍催化剂(II-6)的合成方法如实施例7,其中,镍催化剂(II-6)的产量为0.72g,产率为84%。The synthesis method of nickel catalyst (II-6) is as shown in Example 7, wherein the output of nickel catalyst (II-6) is 0.72 g, and the yield is 84%.

质谱分析的结果MALDI-TOF(m/z):计算值C45H40Br2N2NiO2:859.33,测试值:779.132[M-Br]+Results of mass spectrometry analysis: MALDI-TOF (m/z): calculated for C 45 H 40 Br 2 N 2 NiO 2 : 859.33, found: 779.132 [M-Br] + .

测试例1Test Example 1

对本公开中镍催化剂(II-1)和镍催化剂(II-2)通过密度泛函理论(DFT)计算得到了两个模型分子Ni1+、Ni2+。此外,通过使用SambVca 2.1A工具得到了Ni1+、Ni2+的优化结构立体图,其结构如图18、图19,相关参数记录于下表1。The nickel catalyst (II-1) and the nickel catalyst (II-2) in the present disclosure were calculated by density functional theory (DFT) to obtain two model molecules Ni1 + and Ni2 + . In addition, the optimized structural stereograms of Ni1 + and Ni2 + were obtained by using the SambVca 2.1A tool, and their structures are shown in Figures 18 and 19, and the relevant parameters are recorded in Table 1 below.

表1Table 1

Ni1+ Ni1 + Ni2+ Ni2 + ΔG(KJ/mol)ΔG(KJ/mol) 19.819.8 27.127.1

结果表明,镍中心的埋藏体积为:Ni2+(54.7%)>Ni1+(52.9%),这表明本公开中提出噁唑结构的空间效应有效抑制了链式行走过程,进而导致乙烯聚合物产生不同的支化度。乙烯配位能垒的DFT计算结果表明:Ni2+(27.2kJ/mol)>Ni1+(19.8kJ/mol),表明较大的空间位阻可以抑制乙烯的配位,从而降低Ni2的活性和聚合物的分子量。The results show that the buried volume of the nickel center is: Ni2 + (54.7%)>Ni1 + (52.9%), which indicates that the steric effect of the oxazole structure proposed in the present disclosure effectively inhibits the chain walking process, thereby leading to different branching degrees of ethylene polymers. The DFT calculation results of the ethylene coordination barrier show: Ni2 + (27.2kJ/mol)>Ni1 + (19.8kJ/mol), indicating that larger steric hindrance can inhibit the coordination of ethylene, thereby reducing the activity of Ni2 and the molecular weight of the polymer.

测试例2Test Example 2

使用本公开制备得到的具有噁唑结构的镍催化剂在烯烃均聚反应中的方法包括:在手套箱中,在氮气氛围下,向350mL高压釜(带有磁力搅拌装置、油浴加热装置和温度计)的耐压瓶中加入18mL正庚烷、200eq Et2AlCl。将容器连接到高压管线并对管道进行抽真空。使用油浴将容器控制在适当的温度,通过注射器溶解在2mL二氯甲烷的一定量的实施例中制备的镍催化剂注入聚合体系中。关闭阀门,调节乙烯压力为8大气压后,反应30min。停止反应,打开反应釜,得到的聚合物真空抽干溶剂,得到黄色油状物。其中,不同具有噁唑结构的镍催化剂在不同反应条件下对催化乙烯均聚反应的影响记录如下表2:The method for using the nickel catalyst with oxazole structure prepared by the present disclosure in olefin homopolymerization reaction includes: in a glove box, under a nitrogen atmosphere, 18mL of n-heptane and 200eq of Et2AlCl are added to a pressure-resistant bottle of a 350mL autoclave (with a magnetic stirring device, an oil bath heating device and a thermometer). The container is connected to a high-pressure pipeline and the pipeline is evacuated. The container is controlled at an appropriate temperature using an oil bath, and the nickel catalyst prepared in a certain amount of the embodiment dissolved in 2mL of dichloromethane is injected into the polymerization system by a syringe. The valve is closed, and after adjusting the ethylene pressure to 8 atmospheres, the reaction is carried out for 30min. The reaction is stopped, the reactor is opened, and the obtained polymer is vacuum-drained to obtain a yellow oily substance. Among them, the effects of different nickel catalysts with oxazole structure on catalytic ethylene homopolymerization under different reaction conditions are recorded in Table 2 as follows:

表2Table 2

a表2中聚合反应条件为:镍催化剂=2μmol,反应时间=30min,正庚烷(Hep)=18mL,乙烯压力=8atm。聚合至少重复次数在2次以上。b活性=106g·mol-1·h-1c分子量测定是由1HNMR计算而得,氘代氯仿为溶剂。d聚乙烯的支化度(B)由1H NMR分析确定。 a The polymerization conditions in Table 2 are: nickel catalyst = 2 μmol, reaction time = 30 min, n-heptane (Hep) = 18 mL, ethylene pressure = 8 atm. The polymerization was repeated at least 2 times. b Activity = 10 6 g·mol -1 ·h -1 . c Molecular weight determination was calculated by 1 H NMR, deuterated chloroform was used as solvent. d The degree of branching (B) of polyethylene was determined by 1 H NMR analysis.

表2中Ni1对应实施例7制备的镍催化剂(II-1);Ni2对应实施例8制备的镍催化剂(II-2);Ni3对应实施例9制备的镍催化剂(II-3);Ni4对应实施例10制备的镍催化剂(II-4);Ni5对应实施例11制备的镍催化剂(II-5)。In Table 2, Ni1 corresponds to the nickel catalyst (II-1) prepared in Example 7; Ni2 corresponds to the nickel catalyst (II-2) prepared in Example 8; Ni3 corresponds to the nickel catalyst (II-3) prepared in Example 9; Ni4 corresponds to the nickel catalyst (II-4) prepared in Example 10; and Ni5 corresponds to the nickel catalyst (II-5) prepared in Example 11.

在20℃和8atm乙烯压力下,配合物Ni1具有优异的催化活性(2.6×106g·mol-1·h-1)以及催化产生了适当分子量(1750g·mol-1)的聚合物。在相同条件下,与Ni1相比,空间体积更大的配合物Ni2产生的聚合物具有更低的活性和分子量(表2,第1、2行)。At 20°C and 8 atm ethylene pressure, complex Ni1 has excellent catalytic activity (2.6×10 6 g·mol -1 ·h -1 ) and catalytically produces polymers with a suitable molecular weight (1750 g·mol -1 ). Under the same conditions, the polymer produced by the sterically larger complex Ni2 has lower activity and molecular weight than Ni1 (Table 2, rows 1 and 2).

在20℃,8atm乙烯压力下,Ni1、Ni2催化产生的寡聚物的支化度为:Ni1(102/1000C)>Ni2(68/1000C)。活性和分子量随着乙烯压力的增加而进一步增加,同时寡聚物的支化度降低(表2,第5、6行)。此外,在该体系的所有寡聚物的1HNMR谱中都能观察到了内双键,这可能是由于聚合物的链式行走过程产生的。At 20°C and 8 atm ethylene pressure, the branching degree of oligomers produced by Ni1 and Ni2 is: Ni1 (102/1000C) > Ni2 (68/1000C). The activity and molecular weight further increase with the increase of ethylene pressure, while the branching degree of the oligomer decreases (Table 2, rows 5 and 6). In addition, internal double bonds can be observed in the 1 H NMR spectra of all oligomers in this system, which may be generated by the chain walking process of the polymer.

通过比较Ni2~Ni5的催化聚合过程,进一步研究了配体骨架结构的电子效应(表1,第6~9行)。与配合物Ni2相比,具有给电子基团(OMe)的配合物Ni3的活性较低,而具有缺电子基团(CF3)的配合物Ni4的乙烯寡聚活性较高。这主要是由于亲电性的增加提高了乙烯配位的速率。聚乙烯产物的分子量依次为:Ni3>Ni2>Ni4,这主要是由于亲电性的提高使链转移率增加。Ni2~Ni4得到的寡聚物的支化度依次为:Ni4>Ni2>Ni3,这很大程度上是由于亲电性的提高使链的重复β-H消除和烯烃重新插入的速率提高了。与配合物Ni2相比,以萘为骨架的配合物Ni5表现出更高的活性和支化度,以及更低的分子量(表2,第9行)。这与Ni4的趋势一致,产生此结果的主要因素是萘基的电子效应。这些结果表明,催化剂的电子效应在一定程度上影响了催化剂的活性。By comparing the catalytic polymerization process of Ni2 to Ni5, the electronic effect of the ligand skeleton structure was further studied (Table 1, rows 6 to 9). Compared with the complex Ni2, the complex Ni3 with an electron-donating group (OMe) has a lower activity, while the complex Ni4 with an electron-deficient group (CF 3 ) has a higher ethylene oligomerization activity. This is mainly due to the increase in electrophilicity, which increases the rate of ethylene coordination. The molecular weight of the polyethylene products is: Ni3>Ni2>Ni4, which is mainly due to the increase in electrophilicity, which increases the chain transfer rate. The branching degree of the oligomers obtained from Ni2 to Ni4 is: Ni4>Ni2>Ni3, which is largely due to the increase in electrophilicity, which increases the rate of repeated β-H elimination and olefin reinsertion of the chain. Compared with the complex Ni2, the complex Ni5 with naphthalene as the skeleton shows higher activity and branching degree, as well as lower molecular weight (Table 2, row 9). This is consistent with the trend of Ni4, and the main factor producing this result is the electronic effect of the naphthyl group. These results show that the electronic effect of the catalyst affects the activity of the catalyst to a certain extent.

测试例3Test Example 3

使用本公开制备得到的具有噁唑结构的镍催化剂在烯烃与极性单体共聚反应中的方法包括:The method of using the nickel catalyst having an oxazole structure prepared by the present disclosure in the copolymerization reaction of olefins and polar monomers includes:

在手套箱中,在氮气氛围下,向350mL高压釜(带有磁力搅拌装置、油浴加热装置和温度计)的耐压瓶中加入一定量的正庚烷、极性单体与Et2AlCl。将容器连接到高压管线并对管道进行抽真空。使用水浴将容器控制在适当的温度,通过注射器将所溶解在2mL二氯甲烷的一定量的实施例中制备的镍催化剂注入聚合体系中。关闭阀门,调节乙烯压力为8大气压后,反应1小时。停止反应,打开反应釜,得到的聚合物真空抽干溶剂。其中,不同具有噁唑结构的镍催化剂催化烯烃和极性单体共聚反应的结果记录如下表3:In a glove box, under a nitrogen atmosphere, a certain amount of n-heptane, polar monomer and Et2AlCl were added to a pressure bottle of a 350 mL autoclave (with a magnetic stirring device, an oil bath heating device and a thermometer). The container was connected to a high-pressure pipeline and the pipeline was evacuated. The container was controlled at an appropriate temperature using a water bath, and a certain amount of the nickel catalyst prepared in the embodiment dissolved in 2 mL of dichloromethane was injected into the polymerization system through a syringe. The valve was closed, and the ethylene pressure was adjusted to 8 atmospheres, and the reaction was carried out for 1 hour. The reaction was stopped, the reactor was opened, and the solvent was vacuum-drained from the obtained polymer. The results of the copolymerization of olefins and polar monomers catalyzed by different nickel catalysts having an oxazole structure are recorded in the following Table 3:

表3Table 3

a表3中聚合反应条件为:Ni催化剂=10μmol,反应时间=1h,乙烯压力=8atm,Et2AlCl=200eq,正庚烷、二氯甲烷、Et2AlCl和极性单体总体积=20mL,时间=1h。聚合至少重复次数在2次以上,b活性=105g·mol-1·h-1c分子量测定是由1HNMR计算而得,氘代氯仿为溶剂.d极性单体的插入比通过1H NMR测定。eEt2AlCl=2000eq。 a The polymerization conditions in Table 3 are: Ni catalyst = 10 μmol, reaction time = 1 h, ethylene pressure = 8 atm, Et 2 AlCl = 200 eq, total volume of n-heptane, dichloromethane, Et 2 AlCl and polar monomer = 20 mL, time = 1 h. The polymerization was repeated at least 2 times. b Activity = 10 5 g·mol -1 ·h -1 , c Molecular weight was determined by 1 H NMR, deuterated chloroform was used as solvent. d Insertion ratio of polar monomer was determined by 1 H NMR. e Et 2 AlCl = 2000 eq.

在乙烯和6-氯-1-己烯的共聚反应中(表3,第1、2行),催化剂Ni1显示出比Ni2更高的极性单体插入比。这可能是因为空间位阻较大的配合物Ni2阻碍了极性单体的配位。由于生物可再生的十一烯酸对镍金属中心有轻微的毒性,因此选择其进行共聚反应。乙烯与十一烯酸的共聚反应具有较高的活性(105g·mol-1·h-1)和适当的极性单体插入比(0.4~0.8%),Ni1产生了具有较低极性单体插入比(0.8%)和较低分子量的共聚物(表3,第3行)。Ni2产生了具有更高活性和更低分子量、更低插入比(0.4%)的共聚物(表3,第4行)。Ni2表现出的活性和聚合物分子量降低,以及极性单体的插入比降低(表3,第4行),这类似于上述乙烯与6-氯-1-己烯的共聚过程,并归因于空间/电子效应。In the copolymerization of ethylene and 6-chloro-1-hexene (Table 3, rows 1 and 2), catalyst Ni1 showed a higher polar monomer insertion ratio than Ni2. This may be because the sterically more hindered complex Ni2 hinders the coordination of polar monomers. Biorenewable undecylenic acid was selected for copolymerization because it is slightly toxic to nickel metal centers. The copolymerization of ethylene and undecylenic acid has high activity (10 5 g·mol -1 ·h -1 ) and appropriate polar monomer insertion ratio (0.4-0.8%), and Ni1 produces copolymers with lower polar monomer insertion ratio (0.8%) and lower molecular weight (Table 3, row 3). Ni2 produces copolymers with higher activity and lower molecular weight and lower insertion ratio (0.4%) (Table 3, row 4). The decrease in activity and polymer molecular weight, as well as the decrease in polar monomer insertion ratio (Table 3, row 4) shown by Ni2 are similar to the above-mentioned copolymerization process of ethylene and 6-chloro-1-hexene and are attributed to steric/electronic effects.

以上所述的具体实施例,对本公开的目的、技术方案和有益效果进行了进一步详细说明,应理解的是,以上所述仅为本公开的具体实施例而已,并不用于限制本公开,凡在本公开的精神和原则之内,所做的任何修改、等同替换、改进等,均应包含在本公开的保护范围之内。The specific embodiments described above further illustrate the purpose, technical solutions and beneficial effects of the present disclosure. It should be understood that the above description is only a specific embodiment of the present disclosure and is not intended to limit the present disclosure. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present disclosure should be included in the protection scope of the present disclosure.

Claims (10)

1. A ligand compound with an oxazole structure is shown in a formula (I),
wherein R is 1 Selected from any one of methyl, benzhydrylMeaning one;
ar is selected from one of naphthyl, benzothienyl and substituted or unsubstituted benzene,
when the above-mentioned substituted or unsubstituted benzene has a substituent, the substituent is selected from an electron withdrawing substituent or an electron donating substituent.
2. The ligand compound according to claim 1, wherein the electron withdrawing substituent is selected from any one of trifluoromethyl, hydroxyl, and nitro, and the electron donating substituent is selected from methoxy.
3. The ligand compound according to claim 1, wherein any one of the following formulas (i-a) to (i-c):
wherein R is 2 Is selected from any one of trifluoromethyl, hydroxyl, nitro and methoxy.
4. The ligand compound of claim 1, wherein the structural formula is as follows:
5. a method of preparing the ligand compound of any one of claims 1 to 4, comprising:
reacting a compound shown as a formula (A) with a methyl ketonate compound to obtain a compound shown as a formula (B);
reacting a compound shown as a formula (B) with 2-amino-2-methyl-1-propanol to obtain a compound shown as a formula (C);
the compound shown in the formula (C) is subjected to self-isomerization and dehydration reaction to obtain the compound shown in the formula (I).
6. The method of claim 5, wherein,
the compound (A) and the methyl ketoacid ester compound are mixed in a molar ratio of 1:1, p-toluenesulfonic acid monohydrate is added, water is separated and reflux reacted for 40 hours at 140-145 ℃, and the compound (B) is obtained after recrystallization;
the compound (B) and 2-amino-2-methyl-1-propanol are mixed in a molar ratio of 1:2-1:2.5, react for 24 hours at 140-145 ℃, and are separated to obtain the compound (C);
and (3) after the compound (C) is dissolved, adding triethylamine, 4-dimethylaminopyridine and 4-toluenesulfonyl chloride, and reacting for 40 hours at 80-85 ℃ to obtain the ligand compound.
7. A nickel catalyst with an oxazole structure is shown in a formula (II),
wherein R is 1 Any one selected from methyl and benzhydryl;
ar is selected from one of naphthyl, benzothienyl and substituted or unsubstituted benzene,
when the above-mentioned substituted or unsubstituted benzene has a substituent, the substituent is selected from an electron withdrawing substituent or an electron donating substituent;
wherein the electron withdrawing substituent is preferably any one of trifluoromethyl, hydroxyl and nitro;
the electron donating substituent is preferably methoxy.
8. The nickel catalyst according to claim 7, wherein the structural formula is represented by any one of the following formulas (II-a) to (II-c):
wherein R is 2 Including any one of trifluoromethyl, hydroxy, nitro and methoxy.
9. The nickel catalyst according to claim 7 or 8, wherein the structural formula is as follows:
10. use of the nickel catalyst according to any of claims 7 to 9 for the preparation of polyolefins, comprising the preparation of polyolefins by polymerization using the nickel catalyst having an oxazole structure as catalyst.
CN202311259727.7A 2023-09-27 2023-09-27 Ligand compound with oxazole structure, preparation method thereof and nickel catalyst Withdrawn CN117327027A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311259727.7A CN117327027A (en) 2023-09-27 2023-09-27 Ligand compound with oxazole structure, preparation method thereof and nickel catalyst

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202311259727.7A CN117327027A (en) 2023-09-27 2023-09-27 Ligand compound with oxazole structure, preparation method thereof and nickel catalyst

Publications (1)

Publication Number Publication Date
CN117327027A true CN117327027A (en) 2024-01-02

Family

ID=89294595

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202311259727.7A Withdrawn CN117327027A (en) 2023-09-27 2023-09-27 Ligand compound with oxazole structure, preparation method thereof and nickel catalyst

Country Status (1)

Country Link
CN (1) CN117327027A (en)

Similar Documents

Publication Publication Date Title
CN102180910B (en) Asymmetrical alpha-diimine nickel complex catalyst and preparation method and application thereof
CN108383739B (en) A kind of aromatic amine with hydroxyl and its α-diimine complex and its application in olefin polymerization
CN113135828B (en) Aromatic amine, alpha-diimine ligand and nickel catalyst based on rigid terphenyl structure and preparation method and application thereof
CN110092744B (en) High-thermal-stability tertiary-butyl-containing asymmetric diimine pyridine complex, and preparation method and application thereof
CN110483748A (en) A kind of bipyridyl bis-phenol-Al catalysts being used to prepare unsaturated polyester (UP) and preparation method
CN109957049B (en) Asymmetric (α-diimine) nickel olefin catalyst and preparation method and application thereof
CN111943974B (en) Metal complex, preparation method and application thereof
CN108794545A (en) It is used to prepare the alpha-nickel diimine compound of asymmetry containing tertiary butyl, the Preparation method and use of ultra-high molecular weight polyethylene elastomer
CN109956980B (en) Ethylidene acenaphthene asymmetric alpha-diimine nickel catalyst and preparation method and application thereof
CN105153239A (en) Diamine nickel complex, and preparation method and application thereof
CN109956979B (en) Heat-resistant asymmetric alpha-diimine nickel olefin catalyst and preparation method and application thereof
CN109988100B (en) Nitro-enhanced thermal stability and catalytic activity of asymmetric diiminopyridine complex, its preparation method and application
CN110386954B (en) Asymmetric fused ring pyridine imino containing complex and preparation method and application thereof
CN110483586A (en) Big steric hindrance ketimide Raney nickel and its ligand compound, preparation method and application
CN117327027A (en) Ligand compound with oxazole structure, preparation method thereof and nickel catalyst
CN109957051B (en) Vinylideneacenaphthene α-diimine nickel olefin catalyst and its preparation method and application
EP1994040A1 (en) Polymerisation of ethylene and alpha-olefins with phosphino-iminophenol complexes
WO2007009976A1 (en) Polymerisation catalyst system based on monooxime ligands
CN110183496A (en) Pyridine diimine class dual-nuclei structure model, preparation method and application
CN1422874A (en) Olefine polymerization catalyst, synthesis method and its use
CN101274940B (en) Novel bridged beta-diketiminato zirconium compound, preparation thereof and application thereof
Ji et al. Zirconium and hafnium complexes with new tetra-azane ligands: Synthesis, characterization and catalytic properties for ethylene polymerization
CN115745935B (en) Coumarin type catalyst ligand, complex catalyst and application thereof
CN107827935B (en) A kind of α-diimine nickel complex with butanedione skeleton and preparation method and application thereof
CN117658898A (en) Pyridinediimide cobalt complex used to prepare low molecular weight highly linear polyethylene and its preparation method and application

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20240102